Madrigal Pharmaceuticals (MDGL)

• Market cap: $9.7B
• 1 day: -0.44%
• 5 days: 0.28%
• 1 month: 2.25%
• 3 months: 39.86%
• 6 months: 35.52%
• Year to date: 38.68%
• 1 year: 101.3%
• 5 years: 252.38%
• 10 years: 509.47%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Employees: 528